Phenylbutazone, a New Long-Acting Agent that can Improve the Peptide Pharmacokinetic Based on Serum Albumin as a Drug Carrier

    loading  Checking for direct PDF access through Ovid

Abstract

As a NPY-2 receptor agonist, PYY24–36-Leu31 is reported to suppress appetite and has a potential in obesity treatment, but its short half-life limits the clinical application. The use of chemical modification to improve interactions with human serum albumin (HSA) is an effective strategy for prolonging the half-lives of peptide analogues. So based on the characteristics that phenylbutazone has a good combination with HSA, we selected a proper linker to link with PYY24–36-Leu31 to create long-acting and highly biologically active PYY24–36-Leu31 conjugates, and successfully find a novel, long-acting PYY24–36-Leu31 conjugate 8 that, when dosed every other day in diet induce obese (DIO) mice for 2 weeks, results in a significant reduction in food intake and body weight and improvement in blood parameter and hepatic steatosis.

Related Topics

    loading  Loading Related Articles